HomeActive Pharmaceutical Ingredients

Active Pharmaceutical Ingredients

Catalog No. Product Name Information
A2857 Anti-Sphingosine-1-phosphate Anti-Sphingosine-1-phosphate is a human IgG1 monoclonal anti-Sphingosine-1-phosphate antibody that targets lysosphingolipids, thereby lowering the concentration of S1P in the extracellular fluid. MW: 145.74 KD.
A2615 Anti-PMEL Anti-PMEL is a monoclonal antibody targeting human PMEL protein. It is used as a target for antibody drug conjugate (ADC) therapy in melanoma. MW :145.38 KD.
A2873 Anti-ICAM3 / CD50 Anti-ICAM3 / CD50 is an IgG1 monoclonal antibody against intercellular adhesion molecules-3 (ICAM-3, also known as CD50)) with the potential to have anti-proliferative activities. MW: 145.22 KD.
A2874 Anti-MUC17 Anti-MUC17 is an IgG1 monoclonal antibody against MUC17, a membrane-bound protein highly expressed on the surface of intestinal cells. MW: 146.66 KD.
A2627 Anti-Complement C5aR1 (G2_anti-C5aR) Anti-Complement C5aR1 (G2_anti-C5aR) is a rat monoclonal antibody that detects Complement 5a receptor (C5aR). It exhibit potent proinflammatory stimulus with immunomodulatory activities. MW :146.08 KD.
A2631 Anti-IL-3Ra / CD123 (SGN-CD123A) Anti-IL-3Ra / CD123 (SGN-CD123A) is an antibody-drug conjugate targeting IL-3 alpha chain receptor (CD123). It is a potent antileukemic agent in treatment of acute myelogenous leukemia(AML). MW :146.14 KD.
A2633 Anti-OX2R / CD200R1 Anti-OX2R / CD200R1 is a monoclonal antibody targeting CD200. It exhibited potential in regulating tissue inflammation during skin wound healing. MW :146.58 KD.
D4060 Mirvetuximab-MMAE Mirvetuximab-MMAE is an ADC targeting FOLR1 (folate receptor 1). It can be used in ovarian and other FRα-positive cancer research. MW :145.96 KD.
A2639 Anti-CEACAM6 / CD66c (NEO-201) Anti-CEACAM6 / CD66c (NEO-201) is a humanized IgG1 monoclonal antibody that targets of CEACAM family. It enhances natural killer cell cytotoxicity against tumor cells. MW :145.48 KD.
D4061 Anti-GPC3 / Glypican-3 (Codrituzumab-MMAE) Anti-GPC3 / Glypican-3 (Codrituzumab-MMAE) is an antibody-drug conjugate (ADC) targeting GPC3 (glypican-3). It induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth and can be used in the research of hepatocellular carcinoma (HCC). MW :145.58 KD.
A2640 Anti-CHI3L1 Anti-CHI3L1 is a monoclonal antibody targeting Chitinase 3–like 1 (CHI3L1). It proves a promising therapy for pulmonary metastasis and progression. MW :147.04 KD.
D4062 Anti-KAAG1 (ADCT-901-MMAE) Anti-KAAG1 (ADCT-901-MMAE) is an ADC composed of a humanized monoclonal antibody (3A4) targeting human KAAG1. It is used for the treatment of advanced solid tumors including platinum resistant ovarian cancer and triple negative breast cancer. MW :145.28 KD.
A2642 Zolbetuximab (Anti-CLDN18.2) Zolbetuximab (Anti-CLDN18.2) is a monoclonal antibody targeting Claudin-18.2. It can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors. MW :150 KD.
A3154 Anti-CDH17 / Cadherin-17 (10C12) Anti-CDH17 / Cadherin-17 (10C12) is a humanized monoclonal antibody targeting Cadherin-17 (CDH17), a prominent cancer biomarker. It has growth inhibitory effect on liver and stomach tumour cells. It can be used as therapeutics for treating lung metastasis of hepatocellular carcinoma (HCC). MW :143.68 KD.
A2643 Anti-CLDN6 (IMAB027) Anti-CLDN6 (IMAB027) is a fully humanized antibody targeting CLDN6. It gets conjugated to monomethyl auristatin E( MMAE) resulting in the potential therapeutic CLDN6–23-ADC. It exhibits antitumor efficacy in ovarian epithelial carcinomas.MW :144.42 KD.
A2899 Margetuximab (Anti-ERBB2 / HER2 / CD340) Margetuximab (Anti-ERBB2 / HER2 / CD340) is a Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. MW: 146.1 KD.
A3250 Anti-CLDN6 Anti-CLDN6 is a fully humanized antibody targeting Claudin-6 (CLDN6). It is conjugated to MMAE through a cleavable linker, forming a drug conjugate and exhibits anti-tumor activity.
A2646 Anti-CXCL9 Anti-CXCL9 is an antibody targeting CXCL9 chemokine. It has the potemtial of inhibiting inflammation. MW :150 KD.
A3159 Datopotamab (Anti-TROP2) Datopotamab (Anti-TROP2) is an antibody targeting to TROP2. It demonstrates potent antitumor activity and can be used in non-small cell lung cancer (NSCLC) research. MW :145.16 KD.
A2648 Anti-DC-SIGN / CD209 Anti-DC-SIGN / CD209 is a humanized monoclonal antibody that specifically targets DC-SIGN. It inhibits infection caused by human cytomegalovirus (CMV) in immunocompromised patients, namely in organ-transplanted recipients or AIDS patients. ME :146.62 KD.